8-K: Baxter International Exceeds Expectations in Q1 2025, Raises Bottom End of EPS Guidance

Baxter International reports a strong first quarter in 2025, exceeding sales and earnings guidance, and subsequently increasing the lower end of its full-year adjusted EPS outlook.

Summary

• Baxter International Inc. reported its first-quarter 2025 results, with worldwide sales from continuing operations reaching $2.63 billion, a 5% increase on both reported and operational bases.
• U.S. sales increased by 11% on a reported basis and 7% on an operational basis, totaling $1.49 billion.
• International sales were $1.14 billion, a decrease of 1% on a reported basis but an increase of 3% on an operational basis.
• The company's U.S. GAAP diluted earnings per share (EPS) from continuing operations was $0.13.
• Adjusted diluted EPS from continuing operations was $0.55, exceeding the company's previous guidance of $0.47 to $0.50.
• Baxter has increased the bottom end of its full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.55.
• For the second quarter of 2025, the company expects sales growth of 4% to 5% on a reported basis and 1% to 2% on an operational basis, with adjusted EPS of $0.59 to $0.63.
• The Kidney Care business was acquired by Carlyle on January 31, 2025, and is reported as discontinued operations.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with exceeded expectations in sales and EPS, along with increased guidance. However, there are some concerns regarding international sales decline and macroeconomic uncertainties, which temper the overall sentiment.

Positives

• First-quarter sales exceeded previous guidance, growing 5% on both a reported and operational basis.
• Adjusted diluted EPS exceeded previous guidance, coming in at $0.55 compared to the expected range of $0.47 to $0.50.
• Baxter increased the bottom end of its full-year adjusted diluted EPS guidance, now expecting $2.47 to $2.55.
• All three of Baxter's segments (Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals) achieved growth in the first quarter on both a reported and operational basis.
• The company is advancing key strategic priorities, including the introduction of new technologies and product enhancements.

Negatives

• International sales from continuing operations declined 1% on a reported basis.
• Gross margin decreased from 38.6% to 32.8% year-over-year.
• Operating income decreased by 50% year-over-year.
• Pharmaceuticals sales only increased by 1% on a reported basis.

Risks

• Global macroeconomic factors are creating a greater degree of uncertainty in the market.
• The company's ability to achieve the intended benefits of its strategic actions, including the sale of the Kidney Care business, is subject to various risks.
• Integration of acquisitions, such as Hillrom, poses challenges related to organizational structure, personnel capacity, and achieving financial targets.
• Global economic conditions, including inflation, supply chain disruptions, and geopolitical events, could impact the company's operations.
• Product development risks, regulatory approvals, and market acceptance of new products are subject to uncertainty.
• Failures in quality, compliance, or ethics programs could lead to negative consequences.
• Breaches in information technology systems or cyber-attacks could compromise protected information.

Future Outlook

Baxter expects full-year 2025 sales growth from continuing operations of 7% to 8% on a reported basis and 4% to 5% on an operational basis, with adjusted earnings from continuing operations of $2.47 to $2.55 per diluted share. For the second quarter of 2025, the company expects sales growth of 4% to 5% on a reported basis and 1% to 2% on an operational basis, with adjusted EPS of $0.59 to $0.63.

Management Comments

• Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey, said Brent Shafer, chair and interim chief executive officer.
• Baxter today is a more focused and agile organization, well positioned to drive enhanced value for patients, healthcare providers, customers and shareholders through our reinvigorated emphasis on execution, innovation and profitable growth.
• While todays global macroeconomic factors are creating a greater degree of uncertainty in the market, we remain confident in our overarching trajectory.
• The benefits of our operating model in combination with our durable portfolio of medically essential products create a strong foundation to leverage our potential and pursue opportunities to help address our customers most pressing needs in the pursuit of our life-sustaining Mission.

Industry Context

Baxter's focus on innovation and strategic priorities aligns with the broader medtech industry's trend toward developing advanced technologies and solutions to improve patient care and streamline healthcare operations. The company's emphasis on profitable growth and efficiency reflects the industry's need to navigate economic uncertainties and deliver value to shareholders.

Comparison to Industry Standards

• Baxter's 5% revenue growth is comparable to other large-cap medical device companies, such as Medtronic and Johnson & Johnson, which have also reported mid-single-digit growth in recent quarters.
• The adjusted EPS of $0.55 is in line with industry expectations, considering Baxter's ongoing transformation and strategic initiatives.
• The company's focus on innovation, as demonstrated by the launch of the Voalte Linq device and Hemopatch Sealing Hemostat, aligns with the industry's emphasis on developing new and improved products to meet evolving healthcare needs.
• Baxter's strategic actions, including the sale of the Kidney Care business and the integration of Hillrom, are similar to other companies in the industry that are streamlining their operations and focusing on core competencies.

Legal Proceedings

• The company's results of continuing operations in 2025 included charges related to matters involving alleged injury from environmental exposure.

Stakeholder Impact

• The solid performance and increased guidance are positive for shareholders.
• The focus on innovation and new technologies benefits patients and healthcare providers.
• The company's transformation journey and strategic actions may impact employees.

Key Dates

Keywords

Baxter International, financial results, earnings, sales growth, EPS, guidance, medical technology, healthcare, Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals